Greater Philadelphia consistently ranks near the top of desirable locations for Cell and Gene Therapy across all metrics. The metrics linked below analyze Greater Philadelphia’s position in the CGT sector against competitor locations as it relates to Research Infrastructure, Human Capital, Innovation Output, Commercial Activity, and Value Proposition. In the aggregate, Greater Philadelphia ranks 2nd behind only Boston.
Notably, when comparing Greater Philadelphia to its close competitors—Boston, New York, and San Francisco—Greater Philadelphia fails to gain the number one spot in any single category (although ranks first in NIH funding, a subcategory within Research Infrastructure). However, its value proposition ranks significantly higher than these dense and expensive cities, pushing Greater Philadelphia ahead into the second spot overall. Together, the strength of Greater Philadelphia’s cell and gene therapy sector coupled with the livability of the region results in its high ranking
